Moshfeghi Andrew, Garmo Vincent, Sheinson Daniel, Ghanekar Avanti, Abbass Ibrahim
USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Genentech, Inc., South San Francisco, CA, USA.
Clin Ophthalmol. 2020 Oct 29;14:3651-3659. doi: 10.2147/OPTH.S275968. eCollection 2020.
To characterize the natural course of diabetic retinopathy (DR) in contemporary clinical practice.
This was a retrospective analysis of US claims data collected between January 1, 2006, and April 30, 2017. Patients aged ≥18 years with continuous medical and prescription insurance coverage for 18 months before DR diagnosis (index date) and for a follow-up period of 5 years were included (N=14,490). The time and risk of progressing to severe nonproliferative DR (NPDR) or proliferative DR (PDR) and of developing diabetic macular edema (DME) were evaluated over 5 years in patients stratified by DR severity at initial diagnosis.
The estimated probability of progressing to severe NPDR or PDR within 5 years of diagnosis was 17.6% for patients with moderate NPDR versus 5.8% for mild NPDR. The probability of developing DME within 5 years was 62.6%, 44.6%, and 28.4% for patients diagnosed with severe NPDR, moderate NPDR, and PDR, respectively, versus 15.6% for mild NPDR. Among those observed to progress, median time to severe NPDR or PDR was approximately 2.0 years in patients with moderate NPDR, whereas median time to DME was approximately 0.5 years in patients with severe NPDR, 1.3 years in moderate NPDR, and 1.6 years in PDR. Relative to mild NPDR, adjusted hazard ratios (95% confidence interval) for progression to severe NPDR or PDR within 5 years were 3.12 (2.61-3.72) in patients with moderate NPDR, and for incident DME were 5.92 (5.13-6.82), 3.54 (3.22-3.91), and 1.96 (1.80-2.14) in patients with severe NPDR, moderate NPDR, and PDR, respectively.
The risk of DR progression and DME over 5 years was highest among patients diagnosed with moderate and severe NPDR, respectively. Our findings reinforce the importance of close monitoring for these patients to avoid unobserved disease progression toward PDR and/or DME.
在当代临床实践中描述糖尿病视网膜病变(DR)的自然病程。
这是一项对2006年1月1日至2017年4月30日期间收集的美国索赔数据的回顾性分析。纳入年龄≥18岁、在DR诊断(索引日期)前有18个月连续医疗和处方保险覆盖且随访期为5年的患者(N = 14490)。在初始诊断时按DR严重程度分层的患者中,评估5年内进展为重度非增殖性DR(NPDR)或增殖性DR(PDR)以及发生糖尿病性黄斑水肿(DME)的时间和风险。
中度NPDR患者在诊断后5年内进展为重度NPDR或PDR的估计概率为17.6%,而轻度NPDR患者为5.8%。重度NPDR、中度NPDR和PDR患者在5年内发生DME的概率分别为62.6%、44.6%和28.4%,而轻度NPDR患者为15.6%。在观察到病情进展的患者中,中度NPDR患者进展为重度NPDR或PDR的中位时间约为2.0年,而重度NPDR患者发生DME的中位时间约为0.5年,中度NPDR患者为1.3年,PDR患者为1.6年。相对于轻度NPDR,中度NPDR患者5年内进展为重度NPDR或PDR的调整后风险比(95%置信区间)为3.12(2.61 - 3.72),重度NPDR、中度NPDR和PDR患者发生DME的调整后风险比分别为5.92(5.13 - 6.82)、3.54(3.22 - 3.91)和1.96(1.80 - 2.14)。
分别在诊断为中度和重度NPDR的患者中,5年内DR进展和DME的风险最高。我们的研究结果强化了对这些患者密切监测的重要性,以避免未观察到的疾病进展为PDR和/或DME。